Recipharm in talks to make LIDDS' prostate cancer drug-device candidate

By Dan Stanton contact

- Last updated on GMT

Recipharm in talks to make LIDDS' prostate cancer candidate
Recipharm has begun negotiations to manufacture a prostate cancer drug-device candidate for Swedish pharma firm LIDDS.

Helsingborg, Sweden-based LIDDS (Local Intelligent Drug Delivery System) is developing a potential treatment for prostate cancer using its proprietary drug delivery platform.

Liproca Depot comprises of a modified-release formulation of 2-hydroxyflutamid, prepared as a paste, delivered in a pre-filled container/syringe, which also acts as mixing equipment of the paste prior to injection.

Currently in Phase II clinical trials, LIDDS is now looking for a contract manufacturing organisation (CMO) for the scale-up, manufacture and quality assurance of the product and fellow Swedish firm Recipharm says it has begun negotiations to be that partner.

If successful, Recipharm General Manager Maria Lundberg told Outsourcing-Pharma.com production would take place in its facility in Solna, Sweden, to begin with.

“When this platform is implemented, it can be used for more substances and we will be there to support Lidds with their future plans,”​ she said. “This is new technology and specialized equipment is needed. We will need to invest but not expand our facility.”

But the deal is not guaranteed, Lundberg added, saying she was unaware which other manufacturers  – if any – have submitted a tender offer. “This is a very interesting product opportunity, which should be of interest to many CDMOs.”

LIDDS CEO Monica Walter was unable to divulge who else the firm was speaking to and the timelines involved in selecting a partner.

However, she did say LIDDS was looking for a “trusted company with technical capabilities and – depending on clinical trial results – the commercial manufacturing capacity.”

LIDDS holds the IP on the Liproca Depot product, and says it holds a number of advantages over current treatments for prostate cancer.

These include fewer side-effects due to the local administration, reduced dosing frequency and improved patient compliance, and an increased accuracy in dose-positioning due to the injected material being visible with ultrasound.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers